Innovent Biologics Schedules 25 Aug 2026 Board Meeting to Approve 1H26 Results

Bulletin Express

08/10

Innovent Biologics has announced that its board of directors will convene on Tuesday, 25 August 2026 to review, approve and publish the interim results for the six months ended 30 June 2026.

The notice, released on 10 August 2026, confirms that Chairman and Executive Director Dr. De-Chao Michael Yu will preside over the meeting. Executive Directors Mr. Ronald Hao Xi Ede and Ms. Qian Zhang, along with Independent Non-executive Directors Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Mr. Shuyun Chen and Dr. Stephen A. Sherwin, will also participate.

The forthcoming meeting will determine the interim financial statements for the first half of 2026 and authorize their release to the market, providing stakeholders with updated insights into the company’s operational and financial performance.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1180808474"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180808474\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180808474?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 17:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180808474","market":"us","top_or_hot":-1,"title":"Innovent Biologics Schedules 25 Aug 2026 Board Meeting to Approve 1H26 Results","media":"Bulletin Express","content":"<p>Innovent Biologics has announced that its board of directors will convene on Tuesday, 25 August 2026 to review, approve and publish the interim results for the six months ended 30 June 2026.</p>\n<p>The notice, released on 10 August 2026, confirms that Chairman and Executive Director Dr. De-Chao Michael Yu will preside over the meeting. Executive Directors Mr. Ronald Hao Xi Ede and Ms. Qian Zhang, along with Independent Non-executive Directors Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Mr. Shuyun Chen and Dr. Stephen A. Sherwin, will also participate.</p>\n<p>The forthcoming meeting will determine the interim financial statements for the first half of 2026 and authorize their release to the market, providing stakeholders with updated insights into the company’s operational and financial performance.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics Schedules 25 Aug 2026 Board Meeting to Approve 1H26 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics Schedules 25 Aug 2026 Board Meeting to Approve 1H26 Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-08-10 17:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Innovent Biologics has announced that its board of directors will convene on Tuesday, 25 August 2026 to review, approve and publish the interim results for the six months ended 30 June 2026.</p>\n<p>The notice, released on 10 August 2026, confirms that Chairman and Executive Director Dr. De-Chao Michael Yu will preside over the meeting. Executive Directors Mr. Ronald Hao Xi Ede and Ms. Qian Zhang, along with Independent Non-executive Directors Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Mr. Shuyun Chen and Dr. Stephen A. Sherwin, will also participate.</p>\n<p>The forthcoming meeting will determine the interim financial statements for the first half of 2026 and authorize their release to the market, providing stakeholders with updated insights into the company’s operational and financial performance.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信達生物","start_time":0,"source_url":"","article_id":"1180808474","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180808474","pubTimestamp":1786355378,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Innovent Biologics has announced that its board of directors will convene on Tuesday, 25 August 2026 to review, approve and publish the interim results for the six months ended 30 June 2026. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"信达生物定于 2026 年 8 月 25 日召开董事会会议，批准 26 年上半年业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"Innovent Biologics has announced that its board of directors will convene on Tuesday, 25 August 2026 to review, approve and publish the interim results for the six months ended 30 June 2026.\nThe notice, released on 10 August 2026, confirms that Chairman and Executive Director Dr. De-Chao Michael Yu will preside over the meeting. Executive Directors Mr. Ronald Hao Xi Ede and Ms. Qian Zhang, along with Independent Non-executive Directors Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Mr. Shuyun Chen and Dr. Stephen A. Sherwin, will also participate.\nThe forthcoming meeting will determine the interim financial statements for the first half of 2026 and authorize their release to the market, providing stakeholders with updated insights into the company’s operational and financial performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}